uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q17.18 | Q17 | What gene does the drug Ethosuximide target? | The drug Ethosuximide targets 3 genes: CACNA1G, CACNA1I and CACNA1H. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ethosuximide%" OR LOWER(tradeNames_string) LIKE "%ethosuximide%" OR LOWER(drugSynonyms_string) LIKE "%ethosuximide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4742', 'drugName': 'Ethosuximide', 'tradeNames_string': 'Emeside, Ethosuximide, Suxinutin, Zarontin', 'drugSynonyms_string': 'CI-366, CN-10,395, CN-10395, Ethosuximide, Ethosuximidum, NSC-64013, PM-671, Pyknolepsinum', 'linkedDiseasesDrug_string': 'Complex Regional Pain Syndrome (EFO_1001998), Migraine Disorder (MONDO_0005277), Neuropathic Pain (EFO_0005762), Childhood Absence Epilepsy (MONDO_0010826), Irritable Bowel Syndrome (EFO_0000555), Epilepsy (EFO_0000474), Depressive Disorder (MONDO_0002050), Seizure (HP_0001250)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA1G (ENSG00000006283), CACNA1I (ENSG00000100346)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.130 | Q17 | What gene does the drug Insulin Glulisine target? | The drug Insulin Glulisine targets the gene INSR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%insulin glulisine%" OR LOWER(tradeNames_string) LIKE "%insulin glulisine%" OR LOWER(drugSynonyms_string) LIKE "%insulin glulisine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5441', 'drugName': 'Insulin Glulisine', 'tradeNames_string': 'Apidra, Apidra solostar, Ins apidra, Ins apidra opticlik, Ins apidra optiset, Ins apidra solostar', 'drugSynonyms_string': 'Glulisine apidra, HMR 1964, HMR-1964, HMR1964, Insulin Glulisine Recombinant, Insulin glulisine, Insulin glulisine recombinant, Insulin, glulisine, human, Insulin,glulisine,human', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Alzheimer Disease (MONDO_0004975), Down Syndrome (EFO_0001064), Myocardial Infarction (EFO_0000612), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1361 | Q17 | What gene does the drug Cortisone Acetate target? | The drug Cortisone Acetate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cortisone acetate%" OR LOWER(tradeNames_string) LIKE "%cortisone acetate%" OR LOWER(drugSynonyms_string) LIKE "%cortisone acetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1557', 'drugName': 'Cortisone Acetate', 'tradeNames_string': 'Cortate, Cortelan, Cortisone acetate, Cortistab, Cortisyl, Cortone', 'drugSynonyms_string': 'Cortisone, Cortisone 21-acetate, Cortisone Acetate, Cortisone acetate, Cortisone aceticum, NSC-49420', 'linkedDiseasesDrug_string': 'Lateral Epicondylitis (EFO_1001896), Pneumonia (EFO_0003106), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Sympathetic Ophthalmia (EFO_1001205), Pulmonary Tuberculosis (EFO_1000049), Systemic Lupus Erythematosus (MONDO_0007915), Stevens-Johnson Syndrome (EFO_0004276), Iridocyclitis (HP_0001094), Classic Congenital Adrenal Hyperplasia Due To 21-Hydroxylase Deficiency (MONDO_0008728), Nephrotic Syndrome (EFO_0004255), Rotator Cuff Tear (EFO_1001250), Juvenile Idiopathic Arthritis (EFO_0002609), Dermatitis Herpetiformis (EFO_1000684), Atopic Eczema (EFO_0000274), Eye Inflammation (EFO_0005752), Psoriatic Arthritis (EFO_0003778), Congenital Adrenal Hyperplasia (MONDO_0018479), Frozen Shoulder (EFO_1000941), Angioedema (EFO_0005532), Lymphoma (EFO_0000574), Polymyositis (EFO_0003063), Aplastic Anemia (HP_0001915), Tenosynovitis (EFO_1001435), Peptic Ulcer (HP_0004398), Hypercalcemia (HP_0003072), Dermatomyositis (EFO_0000398), Exfoliative Dermatitis (EFO_0009456), Primary Adrenal Insufficiency (MONDO_0015128), Contact Dermatitis (EFO_0005319), Thrombocytopenia (HP_0001873), Asthma (MONDO_0004979), Synovitis (EFO_0008997), Meningeal Tuberculosis (EFO_1000039), Rheumatoid Arthritis (EFO_0000685), Subacute Thyroiditis (EFO_1001194), Erythema Multiforme (EFO_1000694), Hemolytic Anemia (EFO_0005558), Allergic Disease (MONDO_0005271), Gout (EFO_0004274), Iritis (EFO_1000997), Ophthalmic Herpes Zoster (EFO_0007403), Osteoarthritis (MONDO_0005178), Leukemia (EFO_0000565), Enteritis (MONDO_0043579), Seborrheic Dermatitis (EFO_1000764), Posterior Uveitis (EFO_1001119)', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_71', 'drugName': 'Hydrocortisone Acetate', 'tradeNames_string': 'Barquinol hc, Chloromycetin hydrocort, Colifoam, Cortef acetate, Cortifoam, Cortril, Cortucid, Dricort, Epifoam, Framycort, Fucidin h, Genticin hc, Gentisone hc, Gppe ear susp, Gppe eye crm, Gppe foam aero, Hc45 hydrocort, Hemsol-hc, Hepacort plus, Hydrocal, Hydrocortisone acetate, Hydrocortone, Lanacort, Micort-hc, Neo-cortef, Orabase hca', 'drugSynonyms_string': 'Cortisol 21-acetate, Hydrocortisone 21-acetate, Hydrocortisone Acetate, Hydrocortisone acetate, Hydrocortisoni acetas, NSC-741', 'linkedDiseasesDrug_string': 'Vitiligo (EFO_0004208), Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752), Atopic Eczema (EFO_0000274), Inflammation (MP_0001845), Skin Disease (EFO_0000701), Depressive Disorder (MONDO_0002050), Pruritus (HP_0000989)', 'yearOfFirstApproval': 1951, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1393', 'drugName': 'Fludrocortisone Acetate', 'tradeNames_string': 'Astonin, Florinef, Fludrocortisone acetate, Fludrocortone, Panotile', 'drugSynonyms_string': 'Fludrocortisone 21-acetate, Fludrocortisone acetate, Fludrocortisoni acetas, Fluorhydrocortisone acetate, Fluorocortisol acetate, NSC-15186, Scherofluron', 'linkedDiseasesDrug_string': 'Primary Adrenal Insufficiency (MONDO_0015128), Septic Shock (EFO_0006834), Sensorineural Hearing Loss (EFO_1001176), Congenital Adrenal Hyperplasia (MONDO_0018479), Covid-19 (MONDO_0100096), Parkinson Disease (MONDO_0005180), Melanoma (EFO_0000756), Chronic Primary Adrenal Insufficiency (MONDO_0015129), Ovarian Hyperstimulation Syndrome (MONDO_0011972), Depressive Disorder (MONDO_0002050), Adrenogenital Syndrome (MONDO_0015898), Severe Acute Respiratory Syndrome (EFO_0000694)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C2 (ENSG00000151623)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1291 | Q17 | What gene does the drug Tricetamide target? | The drug Tricetamide is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: JAK3 and JAK1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tricetamide%" OR LOWER(tradeNames_string) LIKE "%tricetamide%" OR LOWER(drugSynonyms_string) LIKE "%tricetamide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_970', 'drugName': 'Tricetamide', 'tradeNames_string': '', 'drugSynonyms_string': 'R-548, Tricetamide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'JAK1 (ENSG00000162434), JAK3 (ENSG00000105639)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_971', 'drugName': 'Tricetamide', 'tradeNames_string': '', 'drugSynonyms_string': 'R-548, Tricetamide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'JAK1 (ENSG00000162434), JAK3 (ENSG00000105639)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1969 | Q17 | What gene does the drug Lithium Carbonate target? | The drug Lithium Carbonate targets 3 genes: GSK3B, GSK3A and IMPA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lithium carbonate%" OR LOWER(tradeNames_string) LIKE "%lithium carbonate%" OR LOWER(drugSynonyms_string) LIKE "%lithium carbonate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3119', 'drugName': 'Lithium Carbonate', 'tradeNames_string': 'Camcolit 250, Camcolit 400, Eskalith, Eskalith cr, Liskonum, Lithane, Lithium carbonate, Lithobid, Lithonate, Lithotabs, Phasal', 'drugSynonyms_string': 'CP-15,467-61, CP-15467-61, CP-1546761, Lithium carbonate, NSC-16895', 'linkedDiseasesDrug_string': 'Familial Adenomatous Polyposis (Orphanet_733), Alzheimer Disease (MONDO_0004975), Bipolar I Disorder (EFO_0009963), Multiple Sclerosis (MONDO_0005301), Spinocerebellar Ataxia Type 3 (Orphanet_98757), Spinocerebellar Ataxia Type 1 (MONDO_0008119), Conduct Disorder (EFO_0004216), Differentiated Thyroid Carcinoma (EFO_1002017), Spinal Cord Injury (EFO_1001919), Prostate Cancer (MONDO_0008315), Neutropenia (MONDO_0001475), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Huntington Disease (MONDO_0007739), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Multiple System Atrophy (EFO_1001050), Autism Spectrum Disorder (EFO_0003756), Bone Fracture (EFO_0003931), Concussion (EFO_0011023), Central Nervous System Neoplasm (EFO_1000158), Neuroendocrine Neoplasm (EFO_1001901), Treatment Resistant Depression (EFO_0009854), Aggressive Behavior (EFO_0003015), Small Cell Lung Carcinoma (EFO_0000702), Stroke (EFO_0000712), Progressive Supranuclear Palsy (MONDO_0019037), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Psychosis (EFO_0005407), Brain Cancer (MONDO_0001657), Unipolar Depression (EFO_0003761), Frontotemporal Dementia (MONDO_0017276), Spinocerebellar Ataxia Type 2 (MONDO_0008458), Amyotrophic Lateral Sclerosis (MONDO_0004976), Internal Carotid Artery Stenosis (EFO_0002615), Major Depressive Disorder (MONDO_0002009), Niemann-Pick Disease Type C (MONDO_0018982), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IMPA1 (ENSG00000133731), GSK3A (ENSG00000105723), GSK3B (ENSG00000082701)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3120', 'drugName': 'Lithium Carbonate', 'tradeNames_string': 'Camcolit 250, Camcolit 400, Eskalith, Eskalith cr, Liskonum, Lithane, Lithium carbonate, Lithobid, Lithonate, Lithotabs, Phasal', 'drugSynonyms_string': 'CP-15,467-61, CP-15467-61, CP-1546761, Lithium carbonate, NSC-16895', 'linkedDiseasesDrug_string': 'Familial Adenomatous Polyposis (Orphanet_733), Alzheimer Disease (MONDO_0004975), Bipolar I Disorder (EFO_0009963), Multiple Sclerosis (MONDO_0005301), Spinocerebellar Ataxia Type 3 (Orphanet_98757), Spinocerebellar Ataxia Type 1 (MONDO_0008119), Conduct Disorder (EFO_0004216), Differentiated Thyroid Carcinoma (EFO_1002017), Spinal Cord Injury (EFO_1001919), Prostate Cancer (MONDO_0008315), Neutropenia (MONDO_0001475), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Huntington Disease (MONDO_0007739), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Multiple System Atrophy (EFO_1001050), Autism Spectrum Disorder (EFO_0003756), Bone Fracture (EFO_0003931), Concussion (EFO_0011023), Central Nervous System Neoplasm (EFO_1000158), Neuroendocrine Neoplasm (EFO_1001901), Treatment Resistant Depression (EFO_0009854), Aggressive Behavior (EFO_0003015), Small Cell Lung Carcinoma (EFO_0000702), Stroke (EFO_0000712), Progressive Supranuclear Palsy (MONDO_0019037), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Psychosis (EFO_0005407), Brain Cancer (MONDO_0001657), Unipolar Depression (EFO_0003761), Frontotemporal Dementia (MONDO_0017276), Spinocerebellar Ataxia Type 2 (MONDO_0008458), Amyotrophic Lateral Sclerosis (MONDO_0004976), Internal Carotid Artery Stenosis (EFO_0002615), Major Depressive Disorder (MONDO_0002009), Niemann-Pick Disease Type C (MONDO_0018982), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IMPA1 (ENSG00000133731), GSK3A (ENSG00000105723), GSK3B (ENSG00000082701)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.935 | Q17 | What gene does the drug Benoxinate Hydrochloride target? | The drug Benoxinate Hydrochloride targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%benoxinate hydrochloride%" OR LOWER(tradeNames_string) LIKE "%benoxinate hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%benoxinate hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2819', 'drugName': 'Benoxinate Hydrochloride', 'tradeNames_string': 'Benoxinate hydrochloride', 'drugSynonyms_string': 'Benoxinate hcl, Benoxinate hydrochloride, NSC-759847, Oxibuprocaine chloride, Oxybuprocaine hcl, Oxybuprocaine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.989 | Q17 | What gene does the drug Betazole Hydrochloride target? | The drug Betazole Hydrochloride targets the gene HRH2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%betazole hydrochloride%" OR LOWER(tradeNames_string) LIKE "%betazole hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%betazole hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3149', 'drugName': 'Betazole Hydrochloride', 'tradeNames_string': 'Histalog', 'drugSynonyms_string': 'Ametazole, Betazole dihydrochloride, Betazole hcl, Betazole hydrochloride, Betazolium chloride, NSC-759872', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH2 (ENSG00000113749)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1965 | Q17 | What gene does the drug Alclometasone Dipropionate target? | The drug Alclometasone Dipropionate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alclometasone dipropionate%" OR LOWER(tradeNames_string) LIKE "%alclometasone dipropionate%" OR LOWER(drugSynonyms_string) LIKE "%alclometasone dipropionate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2070', 'drugName': 'Alclometasone Dipropionate', 'tradeNames_string': 'Aclovate, Alclometasone dipropionate, Modrasone', 'drugSynonyms_string': 'Alclometasone, Alclometasone 17,21-dipropionate, Alclometasone dipropionate, NSC-758914, SCH 22219, SCH-22219', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060), Eye Inflammation (EFO_0005752), Skin Disease (EFO_0000701)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.193 | Q17 | What gene does the drug Isoxicam target? | The drug Isoxicam targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%isoxicam%" OR LOWER(tradeNames_string) LIKE "%isoxicam%" OR LOWER(drugSynonyms_string) LIKE "%isoxicam%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1802', 'drugName': 'Isoxicam', 'tradeNames_string': 'Maxicam', 'drugSynonyms_string': 'Isoxicam, NSC-758436, W 8495, W-8495', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1149 | Q17 | What gene does the drug Pentolinium Tartrate target? | The drug Pentolinium Tartrate targets 2 genes: CHRNB4 and CHRNA3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pentolinium tartrate%" OR LOWER(tradeNames_string) LIKE "%pentolinium tartrate%" OR LOWER(drugSynonyms_string) LIKE "%pentolinium tartrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4468', 'drugName': 'Pentolinium Tartrate', 'tradeNames_string': 'Ansolysen', 'drugSynonyms_string': 'NSC-759890, Pentolinium tartrate, Pentolonium tartrate, Pentolonum bitartrate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1001 | Q17 | What gene does the drug Bepotastine target? | The drug Bepotastine targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bepotastine%" OR LOWER(tradeNames_string) LIKE "%bepotastine%" OR LOWER(drugSynonyms_string) LIKE "%bepotastine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3215', 'drugName': 'Bepotastine Besylate', 'tradeNames_string': 'Bepreve', 'drugSynonyms_string': 'BB, Bepotastine Besilate, Bepotastine benzenesulfonate salt, Bepotastine besilate, Bepotastine besylate, TAU-284, Talion', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Rhinitis, Allergic, Perennial (EFO_1001417), Pruritus (HP_0000989)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6339', 'drugName': 'Bepotastine', 'tradeNames_string': 'Bepreve', 'drugSynonyms_string': 'Bepotastine, Betotastine', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Pruritus (HP_0000989), Dermatitis (MONDO_0002406)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1956 | Q17 | What gene does the drug Veralipride target? | The drug Veralipride targets the gene DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%veralipride%" OR LOWER(tradeNames_string) LIKE "%veralipride%" OR LOWER(drugSynonyms_string) LIKE "%veralipride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_775', 'drugName': 'Veralipride', 'tradeNames_string': 'Agreal', 'drugSynonyms_string': 'Agradil, Veralipride', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1657 | Q17 | What gene does the drug Ivabradine target? | The drug Ivabradine targets the gene HCN4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ivabradine%" OR LOWER(tradeNames_string) LIKE "%ivabradine%" OR LOWER(drugSynonyms_string) LIKE "%ivabradine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_32', 'drugName': 'Ivabradine', 'tradeNames_string': 'Corlanor, Procoralan', 'drugSynonyms_string': 'Ivabradine, S-16257', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Orthostatic Hypotension (EFO_0005252), Coronary Artery Disease (EFO_0001645), Non-St Elevation Myocardial Infarction (EFO_0008586), Hypotension (EFO_0005251), Aging (GO_0007568), Atrial Fibrillation (EFO_0000275), Congestive Heart Failure (EFO_0000373), Angina Pectoris (EFO_0003913), Septic Shock (EFO_0006834), Cardiovascular Disease (EFO_0000319), Lymphoma (EFO_0000574), Multiple Organ Failure (EFO_1001373), Tachycardia (HP_0001649), Diastolic Heart Failure (EFO_1000899), Systolic Heart Failure (EFO_1001207), Diabetic Nephropathy (EFO_0000401), Heart Failure (EFO_0003144), Mitral Valve Stenosis (EFO_0007372)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HCN4 (ENSG00000138622)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1183', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_string': 'Corlanor, Procoralan', 'drugSynonyms_string': 'AMG 998, AMG-998, Corlentor, Ivabradine, Ivabradine hcl, Ivabradine hydrochloride, S 16257, S-16257-2', 'linkedDiseasesDrug_string': 'Heart Failure (EFO_0003144), Congestive Heart Failure (EFO_0000373)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HCN4 (ENSG00000138622)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.613 | Q17 | What gene does the drug Dexamethasone Acetate target? | The drug Dexamethasone Acetate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dexamethasone acetate%" OR LOWER(tradeNames_string) LIKE "%dexamethasone acetate%" OR LOWER(drugSynonyms_string) LIKE "%dexamethasone acetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4777', 'drugName': 'Dexamethasone Acetate', 'tradeNames_string': 'Decadron, Decadron-la, Dexamethasone acetate', 'drugSynonyms_string': 'Dectancyl, Dexamethasone 21-acetate, Dexamethasone acetate, Dexamethasone acetate anhydrous, Dexamethasone acetate monohydrate, Dexamethasoni acetas, Dexamethasoni acetas monohydrate, Fortecortin (crystal suspension), NSC-39471', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Tooth Disease (EFO_1001216), Leukemia (EFO_0000565), Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752), Lymphoma (EFO_0000574), Acne (EFO_0003894), Nasal Congestion (HP_0001742), Acute Pancreatitis (EFO_1000652)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.183 | Q17 | What gene does the drug Brilanestrant target? | The drug Brilanestrant is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ESR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%brilanestrant%" OR LOWER(tradeNames_string) LIKE "%brilanestrant%" OR LOWER(drugSynonyms_string) LIKE "%brilanestrant%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4957', 'drugName': 'Brilanestrant', 'tradeNames_string': '', 'drugSynonyms_string': 'ARN-810, Brilanestrant, GDC-0810, Gdc-0810, RG-6046, RG6046', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.305 | Q17 | What gene does the drug Fluphenazine Enanthate target? | The drug Fluphenazine Enanthate targets the gene DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fluphenazine enanthate%" OR LOWER(tradeNames_string) LIKE "%fluphenazine enanthate%" OR LOWER(drugSynonyms_string) LIKE "%fluphenazine enanthate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_905', 'drugName': 'Fluphenazine Enanthate', 'tradeNames_string': 'Moditen enant, Prolixin, Prolixin enanthate', 'drugSynonyms_string': 'Flufenan, Fluphenazine, Fluphenazine enantate, Fluphenazine enanthate, Fluphenazine maleate, Fluphenazini enantas, SQ 16,114, SQ 16144', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Psoriasis (EFO_0000676), Dementia (HP_0000726), Anxiety (EFO_0005230), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.502 | Q17 | What gene does the drug Mifamurtide target? | The drug Mifamurtide targets the gene NOD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mifamurtide%" OR LOWER(tradeNames_string) LIKE "%mifamurtide%" OR LOWER(drugSynonyms_string) LIKE "%mifamurtide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1449', 'drugName': 'Mifamurtide', 'tradeNames_string': '', 'drugSynonyms_string': 'CGP-19835, L-MTP-PE, Mifamurtide, Mifamurtide sodium hydrate, Mifamurtide sodium salt monohydrate, Sodium mifamurtide', 'linkedDiseasesDrug_string': 'Osteosarcoma (EFO_0000637), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NOD2 (ENSG00000167207)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4474', 'drugName': 'Mifamurtide', 'tradeNames_string': '', 'drugSynonyms_string': 'L-MTP-PE, Mifamurtide', 'linkedDiseasesDrug_string': 'Osteosarcoma (EFO_0000637), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NOD2 (ENSG00000167207)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1696 | Q17 | What gene does the drug Doxazosin Mesylate target? | The drug Doxazosin Mesylate targets 3 genes: ADRA1D, ADRA1B and ADRA1A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%doxazosin mesylate%" OR LOWER(tradeNames_string) LIKE "%doxazosin mesylate%" OR LOWER(drugSynonyms_string) LIKE "%doxazosin mesylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_924', 'drugName': 'Doxazosin Mesylate', 'tradeNames_string': 'Cardozin xl, Cardura, Cardura xl, Cascor, Colixil xl, Doxadura, Doxazosin mesylate, Doxzogen xl, Larbex xl, Oxandosin xl, Raporsin xl, Slocinx xl', 'drugSynonyms_string': 'Alfadil, Doxazosin (as mesilate), Doxazosin mesilate, Doxazosin mesylate, Doxazosin methanesulfonate, NSC-759284, UK-33,274-27, UK-33274-27', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537), Benign Prostatic Hyperplasia (EFO_0000284), Myocardial Infarction (EFO_0000612)', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1721 | Q17 | What gene does the drug Enrasentan target? | The drug Enrasentan is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: EDNRA and EDNRB | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%enrasentan%" OR LOWER(tradeNames_string) LIKE "%enrasentan%" OR LOWER(drugSynonyms_string) LIKE "%enrasentan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3107', 'drugName': 'Enrasentan', 'tradeNames_string': '', 'drugSynonyms_string': 'Enrasentan, SB-217242, Sb-217242', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'EDNRB (ENSG00000136160), EDNRA (ENSG00000151617)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3108', 'drugName': 'Enrasentan', 'tradeNames_string': '', 'drugSynonyms_string': 'Enrasentan, SB-217242, Sb-217242', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'EDNRB (ENSG00000136160), EDNRA (ENSG00000151617)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1662 | Q17 | What gene does the drug Prednisolone Sodium Phosphate target? | The drug Prednisolone Sodium Phosphate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%prednisolone sodium phosphate%" OR LOWER(tradeNames_string) LIKE "%prednisolone sodium phosphate%" OR LOWER(drugSynonyms_string) LIKE "%prednisolone sodium phosphate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2586', 'drugName': 'Prednisolone Sodium Phosphate', 'tradeNames_string': 'Codelsol, Cortisate, Hydeltrasol, Inflamase, Inflamase forte, Inflamase mild, Metreton, Orapred, Orapred odt, Pediapred, Predair, Predair forte, Prednisolone sodium phosphate, Predsol, Predsol-n', 'drugSynonyms_string': 'NSC-759187, Prednisolone 21-disodium phosphate, Prednisolone sodium phosphate, Prednisoloni natrii phosphas', 'linkedDiseasesDrug_string': 'Uveitis (EFO_1001231), Acanthamoeba Keratitis (EFO_0007126), Allergic Conjunctivitis (EFO_0007141), Asthma (MONDO_0004979), Nephrotic Syndrome (EFO_0004255), Idiopathic Pulmonary Fibrosis (EFO_0000768), Leukemia (EFO_0000565), Multiple Sclerosis (MONDO_0005301), Chronic Obstructive Pulmonary Disease (EFO_0000341), Otitis Media With Effusion (EFO_0007415), Anemia (MONDO_0002280), Inflammation (MP_0001845), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Pulmonary Fibrosis (EFO_0009448), Allergic Rhinitis (EFO_0005854), Uremia (EFO_1001226), Corneal Scarring (HP_0000559)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1639 | Q17 | What gene does the drug Coltuximab Ravtansine target? | The drug Coltuximab Ravtansine is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD19. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%coltuximab ravtansine%" OR LOWER(tradeNames_string) LIKE "%coltuximab ravtansine%" OR LOWER(drugSynonyms_string) LIKE "%coltuximab ravtansine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_555', 'drugName': 'Coltuximab Ravtansine', 'tradeNames_string': '', 'drugSynonyms_string': 'Coltuximab ravtansine, SAR-3419, SAR3419', 'linkedDiseasesDrug_string': 'Diffuse Large B-Cell Lymphoma (EFO_0000403), Non-Hodgkins Lymphoma (EFO_0005952), Acute Lymphoblastic Leukemia (EFO_0000220)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD19 (ENSG00000177455)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.523 | Q17 | What gene does the drug Linsitinib target? | The drug Linsitinib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: IGF1R and INSR | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%linsitinib%" OR LOWER(tradeNames_string) LIKE "%linsitinib%" OR LOWER(drugSynonyms_string) LIKE "%linsitinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4973', 'drugName': 'Linsitinib', 'tradeNames_string': '', 'drugSynonyms_string': 'ASP-7487, Linsitinib, OSI-906, OSI-906AA', 'linkedDiseasesDrug_string': 'Hepatocellular Carcinoma (EFO_0000182), Head And Neck Malignant Neoplasia (EFO_0006859), Ewing Sarcoma (EFO_0000174), Small Cell Lung Carcinoma (EFO_0000702), Breast Cancer (MONDO_0007254), Skin Cancer (MONDO_0002898), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Cortex Carcinoma (EFO_1000796), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Colorectal Carcinoma (EFO_1001951), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'IGF1R (ENSG00000140443), INSR (ENSG00000171105)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4974', 'drugName': 'Linsitinib', 'tradeNames_string': '', 'drugSynonyms_string': 'ASP-7487, Linsitinib, OSI-906, OSI-906AA', 'linkedDiseasesDrug_string': 'Hepatocellular Carcinoma (EFO_0000182), Head And Neck Malignant Neoplasia (EFO_0006859), Ewing Sarcoma (EFO_0000174), Small Cell Lung Carcinoma (EFO_0000702), Breast Cancer (MONDO_0007254), Skin Cancer (MONDO_0002898), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Cortex Carcinoma (EFO_1000796), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Colorectal Carcinoma (EFO_1001951), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'IGF1R (ENSG00000140443), INSR (ENSG00000171105)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1985 | Q17 | What gene does the drug Tremelimumab target? | The drug Tremelimumab targets the gene CTLA4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tremelimumab%" OR LOWER(tradeNames_string) LIKE "%tremelimumab%" OR LOWER(drugSynonyms_string) LIKE "%tremelimumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_680', 'drugName': 'Tremelimumab', 'tradeNames_string': 'Imjudo', 'drugSynonyms_string': 'CP-675,206, CP-675206, PF-06753388, TICILIMUMAB, Ticilimumab, Tremelimumab, Tremelimumab (genetical recombination), Tremelimumab-actl', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Peritoneal Neoplasm (EFO_1001100), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Squamous Cell Lung Carcinoma (EFO_0000708), Intrahepatic Cholangiocarcinoma (EFO_1001961), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Lymphoid Neoplasm (EFO_0001642), Breast Carcinoma (EFO_0000305), Prostate Adenocarcinoma (EFO_0000673), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Seminoma (MONDO_0003001), Breast Cancer (MONDO_0007254), Gastric Adenocarcinoma (EFO_0000503), Colorectal Neoplasm (EFO_0004142), Lymphoma (EFO_0000574), Female Reproductive System Neoplasm (MONDO_0021148), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Oral Squamous Cell Carcinoma (EFO_0000199), Diffuse Large B-Cell Lymphoma (EFO_0000403), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Dysgerminoma (MONDO_0003002), Pulmonary Neuroendocrine Tumor (EFO_0005220), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Oropharynx Squamous Cell Carcinoma (MONDO_0044704), Carcinoma (EFO_0000313), Biliary Tract Neoplasm (EFO_0003891), Cutaneous Melanoma (EFO_0000389), Urogenital Neoplasm (EFO_0003863), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Hiv Infection (EFO_0000764), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576), Germ Cell Tumor (EFO_0000514)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CTLA4 (ENSG00000163599)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1078 | Q17 | What gene does the drug Cetrorelix Acetate target? | The drug Cetrorelix Acetate targets the gene GNRHR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cetrorelix acetate%" OR LOWER(tradeNames_string) LIKE "%cetrorelix acetate%" OR LOWER(drugSynonyms_string) LIKE "%cetrorelix acetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3467', 'drugName': 'Cetrorelix Acetate', 'tradeNames_string': 'Cetrotide', 'drugSynonyms_string': 'Cetrorelix, Cetrorelix acetate, Cetrotide acetate, D-20761, NS-75A, SB-075 ACETATE', 'linkedDiseasesDrug_string': 'Polycystic Ovary Syndrome (EFO_0000660), Infertility (EFO_0000545)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.482 | Q17 | What gene does the drug Meclofenamate Sodium target? | The drug Meclofenamate Sodium targets 3 genes: PTGS2, PTGS1 and ALOX5. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%meclofenamate sodium%" OR LOWER(tradeNames_string) LIKE "%meclofenamate sodium%" OR LOWER(drugSynonyms_string) LIKE "%meclofenamate sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3724', 'drugName': 'Meclofenamate Sodium', 'tradeNames_string': 'Meclodium, Meclofenamate sodium, Meclomen', 'drugSynonyms_string': 'CL-583.NA SALT, Meclofenamate sodium, Meclofenamate sodium anhydrous, Meclofenamate sodium hydrate, Meclofenamic acid sodium, NSC-757088, Sodium meclofenamate, Sodium meclofenamate monohydrate', 'linkedDiseasesDrug_string': 'Osteoarthritis (MONDO_0005178), Juvenile Idiopathic Arthritis (EFO_0002609), Fever (HP_0001945), Dysmenorrhea (HP_0100607), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3725', 'drugName': 'Meclofenamate Sodium', 'tradeNames_string': 'Meclodium, Meclofenamate sodium, Meclomen', 'drugSynonyms_string': 'CL-583.NA SALT, Meclofenamate sodium, Meclofenamate sodium anhydrous, Meclofenamate sodium hydrate, Meclofenamic acid sodium, NSC-757088, Sodium meclofenamate, Sodium meclofenamate monohydrate', 'linkedDiseasesDrug_string': 'Osteoarthritis (MONDO_0005178), Juvenile Idiopathic Arthritis (EFO_0002609), Fever (HP_0001945), Dysmenorrhea (HP_0100607), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.160 | Q17 | What gene does the drug Tesidolumab target? | The drug Tesidolumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene C5. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tesidolumab%" OR LOWER(tradeNames_string) LIKE "%tesidolumab%" OR LOWER(drugSynonyms_string) LIKE "%tesidolumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1037', 'drugName': 'Tesidolumab', 'tradeNames_string': '', 'drugSynonyms_string': 'LFG-316, LFG316, Lfg316, NOV-4, Tesidolumab', 'linkedDiseasesDrug_string': 'Age-Related Macular Degeneration (EFO_0001365), Intermediate Uveitis (EFO_1000986), Wet Macular Degeneration (EFO_0004683)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'C5 (ENSG00000106804)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1253 | Q17 | What gene does the drug Mitotane target? | The drug Mitotane targets 2 genes: CYP11B1 and CYP11A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mitotane%" OR LOWER(tradeNames_string) LIKE "%mitotane%" OR LOWER(drugSynonyms_string) LIKE "%mitotane%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5754', 'drugName': 'Mitotane', 'tradeNames_string': 'Lysodren, Opddd', 'drugSynonyms_string': "CB 313, CB-313, Chloditan, Chlodithane, Mitotan, Mitotane, NSC-38721, O,p'-ddd, O,p'-ddd,o p'-tde, O,p'-tde, Opeprim", 'linkedDiseasesDrug_string': 'Carcinoma (EFO_0000313), Prostate Cancer (MONDO_0008315), Adrenal Cortex Carcinoma (EFO_1000796), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP11A1 (ENSG00000140459), CYP11B1 (ENSG00000160882)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5755', 'drugName': 'Mitotane', 'tradeNames_string': 'Lysodren, Opddd', 'drugSynonyms_string': "CB 313, CB-313, Chloditan, Chlodithane, Mitotan, Mitotane, NSC-38721, O,p'-ddd, O,p'-ddd,o p'-tde, O,p'-tde, Opeprim", 'linkedDiseasesDrug_string': 'Carcinoma (EFO_0000313), Prostate Cancer (MONDO_0008315), Adrenal Cortex Carcinoma (EFO_1000796), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP11A1 (ENSG00000140459), CYP11B1 (ENSG00000160882)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1205 | Q17 | What gene does the drug Ranitidine Bismuth Citrate target? | The drug Ranitidine Bismuth Citrate targets the gene HRH2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ranitidine bismuth citrate%" OR LOWER(tradeNames_string) LIKE "%ranitidine bismuth citrate%" OR LOWER(drugSynonyms_string) LIKE "%ranitidine bismuth citrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4141', 'drugName': 'Ranitidine Bismuth Citrate', 'tradeNames_string': 'Pylorid, Tritec', 'drugSynonyms_string': 'GR 122311X, GR-122311X, Ranitidine bismuth citrate, Ranitidine bismutrex', 'linkedDiseasesDrug_string': 'Peptic Ulcer (HP_0004398), Helicobacter Pylori Infectious Disease (EFO_1000961), Gastroesophageal Reflux Disease (EFO_0003948)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH2 (ENSG00000113749)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.17 | Q17 | What gene does the drug Rituximab target? | The drug Rituximab targets the gene MS4A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rituximab%" OR LOWER(tradeNames_string) LIKE "%rituximab%" OR LOWER(drugSynonyms_string) LIKE "%rituximab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4195', 'drugName': 'Rituximab', 'tradeNames_string': 'Mabthera, Mabthera rituxan, Rituxan', 'drugSynonyms_string': 'ABP-798, ABP798, BI695500, Bi 695500, Bi-695500, Blitzima, CT-P10, Gp2013, HS-006, HS-006 (RITUXIMAB BIOSIMILAR), HS006, IDEC-102, IDEC-C2B8, Mk-8808, Pf-05280586, R-105 IDEC-102, RG-105, RHCACD20MA, Riabni, Ritemvia, Rituximab, Rituximab (genetical recombination), Rituximab abbs, Rituximab arrx, Rituximab biosimilar - celltrion, Rituximab biosimilar -merck, Rituximab pvvr, Rituximab-abbs, Rituximab-arrx, Rituximab-boehringer ingelheim, Rituximab-ct-p10, Rituximab-pfizer, Rituximab-pvvr, Ruxience, SAIT-101, SAIT101, Truxima, Tuxella, Usp mab 001, monoclonal igg1, Zuberitamab', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Ankylosing Spondylitis (EFO_0003898), Encephalomyelitis (EFO_0001423), Behcet'S Syndrome (EFO_0003780), Lymphoplasmacytic Lymphoma (MONDO_0000432), Vasculitis (EFO_0006803), Lymphoid Neoplasm (EFO_0001642), Graves Ophthalmopathy (EFO_1001466), Pemphigus Vulgaris (EFO_0004719), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Aplastic Anemia (HP_0001915), Granulomatosis With Polyangiitis (EFO_0005297), Myelopathy (HP_0002196), Sickle Cell Anemia (MONDO_0011382), Chronic Progressive Multiple Sclerosis (EFO_0003840), Chronic Fatigue Syndrome (EFO_0004540), Castleman Disease (MONDO_0015564), Malt Lymphoma (EFO_0000191), Hematopoietic And Lymphoid System Neoplasm (MONDO_0002334), T-Lymphoblastic Lymphoma (MONDO_0044917), Chronic Inflammatory Demyelinating Polyneuropathy (EFO_0009538), Follicular Lymphoma (MONDO_0018906), Diabetic Neuropathy (EFO_1000783), Leukemia (EFO_0000565), Churg-Strauss Syndrome (EFO_0007208), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Lymphoma, Aids-Related (EFO_1001365), Classic Hodgkin Lymphoma (MONDO_0009348), Japanese Encephalitis (EFO_0007332), Kidney Disease (EFO_0003086), Schizophrenia (MONDO_0005090), Lupus Nephritis (EFO_0005761), Thrombotic Thrombocytopenic Purpura (MONDO_0018896), Cancer (MONDO_0004992), Fanconi Anemia (MONDO_0019391), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Opsoclonus-Myoclonus Syndrome (EFO_1001383), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Sjogren Syndrome (EFO_0000699), Multiple Sclerosis (MONDO_0005301), Juvenile Dermatomyositis (EFO_0000557), Neuromyelitis Optica (EFO_0004256), Anaplastic Large Cell Lymphoma (EFO_0003032), Myelodysplastic Syndrome (EFO_0000198), Autoimmune Disease (EFO_0005140), Urticaria (EFO_0005531), Mantle Cell Lymphoma (EFO_1001469), Gangliosidosis (MONDO_0017719), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Hemophilia A (MONDO_0010602), Interstitial Lung Disease (EFO_0004244), Diffuse Large B-Cell Lymphoma (EFO_0000403), Antiphospholipid Syndrome (EFO_0002689), Secondary Progressive Multiple Sclerosis (EFO_0008522), Anemia, Hemolytic, Autoimmune (EFO_1001264), Hodgkins Lymphoma (EFO_0000183), Marginal Zone B-Cell Lymphoma (EFO_1000630), Pulmonary Alveolar Proteinosis (MONDO_0001437), Chronic Kidney Disease (EFO_0003884), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Frontotemporal Dementia (MONDO_0017276), Prolymphocytic Leukemia (MONDO_0001023), Colonic Neoplasm (EFO_0004288), Polyneuropathy (EFO_0009562), Neuroblastoma (EFO_0000621), Langerhans Cell Histiocytosis (EFO_1000318), Peripheral Neuropathy (EFO_0003100), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Glomerulonephritis (MONDO_0002462), Aids (EFO_0000765), Mast-Cell Leukemia (EFO_0007359), Idiopathic Pulmonary Fibrosis (EFO_0000768), Focal Segmental Glomerulosclerosis (EFO_0004236), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Primary Biliary Cirrhosis (EFO_1001486), Primary Progressive Multiple Sclerosis (EFO_0008520), Breast Neoplasm (EFO_0003869), Psoriatic Arthritis (EFO_0003778), Lymphoma (EFO_0000574), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Mycosis Fungoides (EFO_1001051), Microscopic Polyangiitis (EFO_1000784), Abnormality Of Blood And Blood-Forming Tissues (HP_0001871), Neoplasm Of Mature B-Cells (EFO_0000096), Glycogen Storage Disease Due To Acid Maltase Deficiency (Orphanet_365), Proteinuria (HP_0000093), Waldenstrom Macroglobulinemia (EFO_0009441), Hairy Cell Leukemia (EFO_1000956), Cutaneous Melanoma (EFO_0000389), Sarcoidosis (MONDO_0019338), Pemphigus (EFO_1000749), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (EFO_1000868), Neoplasm (EFO_0000616), Heart Failure (EFO_0003144), Primary Membranoproliferative Glomerulonephritis (MONDO_0018904), Type 1 Diabetes Mellitus (MONDO_0005147), Stomach Neoplasm (EFO_0003897), Human T-Lymphotropic Virus 1 Infectious Disease (EFO_0007316), Anti-Neutrophil Antibody Associated Vasculitis (EFO_0004826), Lymphoproliferative Syndrome (MONDO_0016537), Macular Degeneration (EFO_0009606), Graft Versus Host Disease (MONDO_0013730), Ocular Cicatricial Pemphigoid (EFO_0008610), Kidney Failure (EFO_1002048), Metastatic Melanoma (EFO_0002617), Systemic Lupus Erythematosus (MONDO_0007915), Burkitts Lymphoma (EFO_0000309), Myasthenia Gravis (EFO_0004991), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Ulcerative Colitis (EFO_0000729), B-Cell Neoplasm (MONDO_0004095), Chronic Myelogenous Leukemia (EFO_0000339), Pneumococcal Infection (EFO_0000772), Nephrotic Syndrome (EFO_0004255), Scleritis (MONDO_0001718), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Stiff-Person Syndrome (EFO_0007498), Bullous Pemphigoid (EFO_0007187), Parkinson Disease (MONDO_0005180), Chronic Myelomonocytic Leukemia (EFO_1001779), Acute Graft Vs. Host Disease (EFO_0004599), Immune System Disease (EFO_0000540), Myopathy (EFO_0004145), Membranous Glomerulonephritis (EFO_0004254), Hemolytic-Uremic Syndrome (MONDO_0001549), Lymphoblastic Lymphoma (MONDO_0000873), Lung Neoplasm (MONDO_0021117), Rheumatoid Arthritis (EFO_0000685), Systemic Scleroderma (EFO_0000717), Lymphoid Leukemia (EFO_0004289), Squamous Cell Carcinoma (EFO_0000707), Pancreatic Neoplasm (EFO_0003860)", 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1550 | Q17 | What gene does the drug Levonorgestrel target? | The drug Levonorgestrel targets the gene PGR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levonorgestrel%" OR LOWER(tradeNames_string) LIKE "%levonorgestrel%" OR LOWER(drugSynonyms_string) LIKE "%levonorgestrel%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2857', 'drugName': 'Levonorgestrel', 'tradeNames_string': 'Athentia next, Emerres, Emerres una, Ezinelle, Fallback solo, Her style, Isteranda, Jadelle, Jaydess, Kyleena, Levonelle, Levonelle one step, Levonelle-2, Levonorgestrel, Levosert, Liletta, Microval, Mirena, Norgeston, Norplant, Norplant Ii, Norplant System, Opcicon one-step, Ovrette, Plan B, Plan b one-step, Postinor-2, Skyla, Upostelle', 'drugSynonyms_string': 'BAY86-5028, Levonorgestrel, Levonorgestrelum, NSC-744007, Norgestrel (-)-form, Norgestrel, (-)-, WY-5104', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Adenomyosis (EFO_1001757), Menorrhagia (HP_0000132), Osteopenia (HP_0000938), Hiv Infection (EFO_0000764), Chronic Lymphocytic Leukemia (EFO_0000095), Chronic Hepatitis B Virus Infection (EFO_0004239), Hemorrhage (MP_0001914), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Non-Alcoholic Steatohepatitis (EFO_1001249), Dysmenorrhea (HP_0100607), Hiv-1 Infection (EFO_0000180), Endometriosis (EFO_0001065), Chronic Hepatitis C Virus Infection (EFO_0004220), Type 2 Diabetes Mellitus (MONDO_0005148), Anorexia Nervosa (MONDO_0005351)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1081 | Q17 | What gene does the drug Perhexiline target? | The drug Perhexiline targets 3 genes: CPT2, CPT1B and MTOR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%perhexiline%" OR LOWER(tradeNames_string) LIKE "%perhexiline%" OR LOWER(drugSynonyms_string) LIKE "%perhexiline%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1726', 'drugName': 'Perhexiline Maleate', 'tradeNames_string': 'Pexid, Pexsig', 'drugSynonyms_string': 'NSC-758409, Perhexiline maleate, Perhexilinum', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), CPT2 (ENSG00000157184), CPT1B (ENSG00000205560)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_919', 'drugName': 'Perhexiline', 'tradeNames_string': '', 'drugSynonyms_string': 'Perhexiline', 'linkedDiseasesDrug_string': 'Diastolic Heart Failure (EFO_1000899), Diabetic Cardiomyopathy (EFO_1001458), Heart Failure (EFO_0003144), Cardiovascular Disease (EFO_0000319), Hypertrophic Cardiomyopathy (EFO_0000538)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), CPT2 (ENSG00000157184), CPT1B (ENSG00000205560)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_918', 'drugName': 'Perhexiline', 'tradeNames_string': '', 'drugSynonyms_string': 'Perhexiline', 'linkedDiseasesDrug_string': 'Diastolic Heart Failure (EFO_1000899), Diabetic Cardiomyopathy (EFO_1001458), Heart Failure (EFO_0003144), Cardiovascular Disease (EFO_0000319), Hypertrophic Cardiomyopathy (EFO_0000538)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), CPT2 (ENSG00000157184), CPT1B (ENSG00000205560)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1724', 'drugName': 'Perhexiline Maleate', 'tradeNames_string': 'Pexid, Pexsig', 'drugSynonyms_string': 'NSC-758409, Perhexiline maleate, Perhexilinum', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), CPT2 (ENSG00000157184), CPT1B (ENSG00000205560)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1725', 'drugName': 'Perhexiline Maleate', 'tradeNames_string': 'Pexid, Pexsig', 'drugSynonyms_string': 'NSC-758409, Perhexiline maleate, Perhexilinum', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), CPT2 (ENSG00000157184), CPT1B (ENSG00000205560)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_920', 'drugName': 'Perhexiline', 'tradeNames_string': '', 'drugSynonyms_string': 'Perhexiline', 'linkedDiseasesDrug_string': 'Diastolic Heart Failure (EFO_1000899), Diabetic Cardiomyopathy (EFO_1001458), Heart Failure (EFO_0003144), Cardiovascular Disease (EFO_0000319), Hypertrophic Cardiomyopathy (EFO_0000538)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), CPT2 (ENSG00000157184), CPT1B (ENSG00000205560)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1972 | Q17 | What gene does the drug Trihexyphenidyl target? | The drug Trihexyphenidyl targets the gene CHRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trihexyphenidyl%" OR LOWER(tradeNames_string) LIKE "%trihexyphenidyl%" OR LOWER(drugSynonyms_string) LIKE "%trihexyphenidyl%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6217', 'drugName': 'Trihexyphenidyl', 'tradeNames_string': '', 'drugSynonyms_string': 'Apo-trihex, NSC-12268, Trihexyphenidyl', 'linkedDiseasesDrug_string': 'Dystonic Disorder (MONDO_0003441), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 1949, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6050', 'drugName': 'Trihexyphenidyl Hydrochloride', 'tradeNames_string': 'Agitane, Artane, Bentex, Broflex, Tremin, Trihexyphenidyl hydrochloride', 'drugSynonyms_string': 'Aparkane, Benzhexol, Benzhexol hydrochloride, Cyclodol, Cyclodolum, NSC-757357, Parcopane, Romparkin, Sedrina, Trihexyphenidyl HCl, Trihexyphenidyl hcl, Trihexyphenidyl hydrochloride, Trihexyphenidyli hydrochloridum, Triphedinon', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1949, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.552 | Q17 | What gene does the drug Codeine Polistirex target? | The drug Codeine Polistirex targets 3 genes: OPRK1, OPRM1 and OPRD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%codeine polistirex%" OR LOWER(tradeNames_string) LIKE "%codeine polistirex%" OR LOWER(drugSynonyms_string) LIKE "%codeine polistirex%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_494', 'drugName': 'Codeine Polistirex', 'tradeNames_string': '', 'drugSynonyms_string': 'Codeine polistirex', 'linkedDiseasesDrug_string': 'Cough (HP_0012735)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1554 | Q17 | What gene does the drug Methamphetamine Hydrochloride target? | The drug Methamphetamine Hydrochloride targets 3 genes: SLC6A4, SLC6A2 and SLC6A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methamphetamine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%methamphetamine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%methamphetamine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5557', 'drugName': 'Methamphetamine Hydrochloride', 'tradeNames_string': 'Desoxyn, Methampex, Methamphetamine hydrochloride', 'drugSynonyms_string': 'Desoxyephedrine hydrochloride, Metamfetamine hydrochloride, Methamphetamine hcl, Methamphetamine hydrochloride, Methamphetamine hydrochloride cii, Methylamfetamine hydrochloride, NSC-169505', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 1943, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.665 | Q17 | What gene does the drug Hexylcaine target? | The drug Hexylcaine targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hexylcaine%" OR LOWER(tradeNames_string) LIKE "%hexylcaine%" OR LOWER(drugSynonyms_string) LIKE "%hexylcaine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_702', 'drugName': 'Hexylcaine Hydrochloride', 'tradeNames_string': 'Cyclaine', 'drugSynonyms_string': 'Hexylcaine HCl, Hexylcaine hcl, Hexylcaine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_3675', 'drugName': 'Hexylcaine', 'tradeNames_string': '', 'drugSynonyms_string': 'Cyclaine, Hexylcaine, Osmocaine', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1626 | Q17 | What gene does the drug Azd9056 target? | The drug Azd9056 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene P2RX7. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%azd9056%" OR LOWER(tradeNames_string) LIKE "%azd9056%" OR LOWER(drugSynonyms_string) LIKE "%azd9056%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4477', 'drugName': 'Azd9056', 'tradeNames_string': '', 'drugSynonyms_string': 'AZD9056, Azd 9056, Azd-9056, Azd9056', 'linkedDiseasesDrug_string': 'Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'P2RX7 (ENSG00000089041)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1028 | Q17 | What gene does the drug Mavacamten target? | The drug Mavacamten targets 7 genes: MYL7, MYH6, MYL3, MYL4, MYL2, MYH7B and MYH7. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mavacamten%" OR LOWER(tradeNames_string) LIKE "%mavacamten%" OR LOWER(drugSynonyms_string) LIKE "%mavacamten%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1036', 'drugName': 'Mavacamten', 'tradeNames_string': 'Camzyos', 'drugSynonyms_string': 'Camzyos, MYK-461, Mavacamten, Myk-461, SAR-439152', 'linkedDiseasesDrug_string': 'Heart Failure (EFO_0003144), Hypertrophic Cardiomyopathy (EFO_0000538)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MYH7 (ENSG00000092054), MYH6 (ENSG00000197616), MYH7B (ENSG00000078814), MYL3 (ENSG00000160808), MYL2 (ENSG00000111245), MYL7 (ENSG00000106631), MYL4 (ENSG00000198336)', 'numberLinkedTargets': 7}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1994 | Q17 | What gene does the drug Varlilumab target? | The drug Varlilumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD27. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%varlilumab%" OR LOWER(tradeNames_string) LIKE "%varlilumab%" OR LOWER(drugSynonyms_string) LIKE "%varlilumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2539', 'drugName': 'Varlilumab', 'tradeNames_string': '', 'drugSynonyms_string': 'CDX-1127, Varlilumab', 'linkedDiseasesDrug_string': 'Astrocytoma (EFO_0000272), Urogenital Neoplasm (EFO_0003863), Oligoastrocytoma (EFO_0000630), Non-Small Cell Lung Carcinoma (EFO_0003060), Gallbladder Carcinoma (EFO_1001956), Oligodendroglioma (EFO_0000632), Lymphoma (EFO_0000574), Melanoma (EFO_0000756), Renal Cell Carcinoma (EFO_0000681), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD27 (ENSG00000139193)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1519 | Q17 | What gene does the drug Concizumab target? | The drug Concizumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene TFPI. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%concizumab%" OR LOWER(tradeNames_string) LIKE "%concizumab%" OR LOWER(drugSynonyms_string) LIKE "%concizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2877', 'drugName': 'Concizumab', 'tradeNames_string': '', 'drugSynonyms_string': 'Anti-TFPI, Concizumab, MAB-2021, NN-7415, NN7415, NNC 0172-0000-2021, NNC-0172-0000-2021, mAb2021', 'linkedDiseasesDrug_string': 'Hemophilia B (MONDO_0010604), Hemophilia A (MONDO_0010602)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'TFPI (ENSG00000003436)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.968 | Q17 | What gene does the drug Mecasermin target? | The drug Mecasermin targets the gene IGF1R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mecasermin%" OR LOWER(tradeNames_string) LIKE "%mecasermin%" OR LOWER(drugSynonyms_string) LIKE "%mecasermin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_672', 'drugName': 'Mecasermin Rinfabate', 'tradeNames_string': 'Iplex, Somatokine', 'drugSynonyms_string': 'Mecasermin Rinfabate Recombinant, Mecasermin rinfabate, Mecasermin rinfabate recombinant, RHIGF-I/RHIGFBP-3', 'linkedDiseasesDrug_string': 'Myotonic Dystrophy (MONDO_0016107), Steinert Myotonic Dystrophy (Orphanet_273), Laron Syndrome (MONDO_0009877), Retinopathy Of Prematurity (EFO_1001158)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IGF1R (ENSG00000140443)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2750', 'drugName': 'Mecasermin', 'tradeNames_string': 'Increlex, Myotrophin', 'drugSynonyms_string': 'CEP-151, Cg-gf2, Cg-igf-1, Igf-1-ec, Igf-1ec, Insulin-like growth factor 1, Insulin-like growth factor i, Mecasermin, Mecasermin recombinant, Mechano growth factor, Pv-802, Pv802, Rh-oligopeptide-2, Sh-oligopeptide-2, Somatomedin c, Somatomedin c, human, Vexxon-igf-1', 'linkedDiseasesDrug_string': "Diabetes Mellitus (EFO_0000400), Bone Disease (EFO_0004260), Growth Hormone Insensitivity Syndrome (MONDO_0015892), Tendinopathy (EFO_1001434), Crohn'S Disease (EFO_0000384), Growth Delay (HP_0001510), Amyotrophic Lateral Sclerosis (MONDO_0004976), Multiple Sclerosis (MONDO_0005301), Noonan Syndrome (MONDO_0018997), Hiv-Associated Lipodystrophy Syndrome (EFO_1001348), Rett Syndrome (MONDO_0010726), Aging (GO_0007568), Anorexia Nervosa (MONDO_0005351), Hypothyroidism (EFO_0004705), Hyperinsulinism (MONDO_0002177), Retinopathy Of Prematurity (EFO_1001158)", 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IGF1R (ENSG00000140443)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1883 | Q17 | What gene does the drug Everolimus target? | The drug Everolimus targets the gene FKBP1A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%everolimus%" OR LOWER(tradeNames_string) LIKE "%everolimus%" OR LOWER(drugSynonyms_string) LIKE "%everolimus%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1925', 'drugName': 'Everolimus', 'tradeNames_string': 'Afinitor, Afinitor disperz, Certican, Votubia, Zortress', 'drugSynonyms_string': '40-o-(2-hydroxyethyl)-rapamycin, Everolimus, RAD 666, RAD-001, RAD-666, RAD001, SDZ-RAD, Sdz rad', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Infection (EFO_0000544), Skin Cancer (MONDO_0002898), Oligodendroglioma (EFO_0000632), Lung Carcinoma (EFO_0001071), Malignant Colon Neoplasm (MONDO_0021063), Lymphangioleiomyomatosis (MONDO_0011705), Malignant Glioma (MONDO_0100342), Neuroendocrine Neoplasm (EFO_1001901), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Thymus Neoplasm (EFO_0002626), Cervical Cancer (MONDO_0002974), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Carcinoid Syndrome (EFO_1000852), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Colorectal Adenocarcinoma (EFO_0000365), Classic Hodgkin Lymphoma (MONDO_0009348), Malignant Pleural Mesothelioma (EFO_0000770), Transitional Cell Carcinoma (EFO_1000601), Kidney Disease (EFO_0003086), Primary Aldosteronism (MONDO_0001422), Glioblastoma Multiforme (EFO_0000519), Germ Cell Tumor (EFO_0000514), Cancer (MONDO_0004992), Pancreatic Neuroendocrine Tumor (EFO_1000045), Non-Hodgkins Lymphoma (EFO_0005952), Islet Cell Tumor (EFO_0007331), Gastrointestinal Stromal Tumor (MONDO_0011719), Central Nervous System Cancer (EFO_0000326), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Neuroendocrine Carcinoma (MONDO_0002120), Uveitis (EFO_1001231), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Bone Sarcoma (MONDO_0021054), Autosomal Dominant Polycystic Kidney Disease (EFO_1001496), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Digestive System Neuroendocrine Neoplasm (MONDO_0024503), Diffuse Large B-Cell Lymphoma (EFO_0000403), Metastasis (EFO_0009708), Small Cell Lung Carcinoma (EFO_0000702), Triple-Negative Breast Cancer (EFO_0005537), Thyroid Cancer (MONDO_0002108), Neurofibromatosis Type 2 (MONDO_0007039), Malignant Peripheral Nerve Sheath Tumor (EFO_0000760), Adenoma Sebaceum (HP_0009720), Cutaneous T-Cell Lymphoma (EFO_0002913), Hodgkins Lymphoma (EFO_0000183), Marginal Zone B-Cell Lymphoma (EFO_1000630), Chronic Kidney Disease (EFO_0003884), Non-Small Cell Lung Carcinoma (EFO_0003060), Hamartoma (EFO_1000634), Peutz-Jeghers Syndrome (MONDO_0008280), Esophageal Carcinoma (EFO_0002916), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Angiomyolipoma (MONDO_0002603), Lymphoma (EFO_0000574), Acute Coronary Syndrome (EFO_0005672), Epilepsy (EFO_0000474), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Cholangiocarcinoma (EFO_0005221), Pulmonary Neuroendocrine Tumor (EFO_0005220), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Abnormality Of Blood And Blood-Forming Tissues (HP_0001871), Gallbladder Cancer (MONDO_0005411), Neurofibromatosis Type 1 (MONDO_0018975), Mesothelioma (EFO_0000588), Carcinoid Tumor (EFO_0004243), Peritoneum Cancer (MONDO_0002087), Waldenstrom Macroglobulinemia (EFO_0009441), Glioma (EFO_0005543), Tuberous Sclerosis (MONDO_0001734), Cutaneous Melanoma (EFO_0000389), Age-Related Macular Degeneration (EFO_0001365), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Urinary Bladder Cancer (MONDO_0001187), Sarcoma (EFO_0000691), Tuberculosis (MONDO_0018076), Polycystic Kidney Disease (EFO_0008620), Synovial Sarcoma (EFO_0001376), Cytomegalovirus Infection (EFO_0001062), Stomach Neoplasm (EFO_0003897), Childhood Ependymoma (MONDO_0003478), Uterine Cancer (MONDO_0002715), Mixed Glioma (MONDO_0003268), Graft Versus Host Disease (MONDO_0013730), Adenoid Cystic Carcinoma (EFO_0000231), Kidney Failure (EFO_1002048), Metastatic Melanoma (EFO_0002617), Coronary Restenosis (EFO_0004224), Endometrial Cancer (MONDO_0011962), Chronic Myelogenous Leukemia (EFO_0000339), Hepatitis C Virus Infection (EFO_0003047), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Familial Atrioventricular Septal Defect (MONDO_0020290), Prostate Cancer (MONDO_0008315), Oligoastrocytoma (EFO_0000630), Male Breast Carcinoma (EFO_0006861), Kidney Angiomyolipoma (EFO_1000312), Acute Graft Vs. Host Disease (EFO_0004599), Immune System Disease (EFO_0000540), Lymphoblastic Lymphoma (MONDO_0000873), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Pten Hamartoma Tumor Syndrome (MONDO_0017623), Systemic Mastocytosis (MONDO_0016586), Progeria (MONDO_0020732), Lymphoid Leukemia (EFO_0004289), Chondrosarcoma (EFO_0000333), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Subependymal Giant Cell Astrocytoma (MONDO_0016693), Meningioma (MONDO_0016642), Nasopharyngeal Neoplasm (EFO_0004252), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576)", 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FKBP1A (ENSG00000088832)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.287 | Q17 | What gene does the drug Dapagliflozin target? | The drug Dapagliflozin targets the gene SLC5A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dapagliflozin%" OR LOWER(tradeNames_string) LIKE "%dapagliflozin%" OR LOWER(drugSynonyms_string) LIKE "%dapagliflozin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1158', 'drugName': 'Dapagliflozin', 'tradeNames_string': 'Forxiga', 'drugSynonyms_string': 'BMS-512148, BMS-512148-05, Dapagliflozin, LYN-045', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Alzheimer Disease (MONDO_0004975), Coronary Artery Disease (EFO_0001645), Covid-19 (MONDO_0100096), Obesity (EFO_0001073), Pulmonary Arterial Hypertension (EFO_0001361), Kidney Failure (EFO_1002048), Aging (GO_0007568), Prostate Carcinoma (EFO_0001663), Atrial Fibrillation (EFO_0000275), Cystinuria (MONDO_0009067), Polycystic Ovary Syndrome (EFO_0000660), Hyperuricemia (EFO_0009104), Breast Cancer (MONDO_0007254), Diabetic Retinopathy (EFO_0003770), Non-Alcoholic Steatohepatitis (EFO_1001249), Pancreatic Carcinoma (EFO_0002618), Myocardial Infarction (EFO_0000612), Albuminuria (EFO_0004285), Hepatic Steatosis (HP_0001397), Chronic Kidney Disease (EFO_0003884), Diastolic Heart Failure (EFO_1000899), Diabetic Neuropathy (EFO_1000783), Ischemia Reperfusion Injury (EFO_0002687), Diabetic Nephropathy (EFO_0000401), Heart Failure (EFO_0003144), Weight Loss (HP_0001824), Metabolic Syndrome (EFO_0000195), Acute Kidney Injury (HP_0001919), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC5A2 (ENSG00000140675)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1962', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_string': 'Farxiga', 'drugSynonyms_string': 'BMS-512148-05, Dapagliflozin, Dapagliflozin propanediol, Dapagliflozin propylene glycol', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148), Heart Failure (EFO_0003144), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC5A2 (ENSG00000140675)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q19.27 | Q19 | Which SNP is most significantly associated with ALS in the Cerebellar Hemisphere? | There are no significantly associated SNPs with ALS in the Cerebellar Hemisphere. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND LOWER(Omic_tissue) = 'cerebellar hemisphere' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.113 | Q19 | Which SNP is most significantly associated with PSP in the Cerebellar Hemisphere? | There are no significantly associated SNPs with PSP in the Cerebellar Hemisphere. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PSP' AND LOWER(Omic_tissue) = 'cerebellar hemisphere' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.83 | Q19 | Which SNP is most significantly associated with LBD in the Spinalcord? | There are no significantly associated SNPs with LBD in the Spinalcord. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'LBD' AND LOWER(Omic_tissue) = 'spinalcord' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.57 | Q19 | Which SNP is most significantly associated with FTD in the Nucleus Accumbens Basal? | There are no significantly associated SNPs with FTD in the Nucleus Accumbens Basal. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'FTD' AND LOWER(Omic_tissue) = 'nucleus accumbens basal' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.45 | Q19 | Which SNP is most significantly associated with FTD in the Amygdala? | There are no significantly associated SNPs with FTD in the Amygdala. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'FTD' AND LOWER(Omic_tissue) = 'amygdala' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.98 | Q19 | Which SNP is most significantly associated with PD in the Liver? | The most significantly associated SNP with PD in the Liver is rs55974014, located in the DND1P1 gene, with an adjusted SMR multi-SNP P-value of 1.42e-12 and a HEIDI value of 6.9873e-01. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND LOWER(Omic_tissue) = 'liver' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1476423', 'topRSID': 'rs55974014', 'Disease': 'PD', 'Omic_tissue': 'Liver', 'p_SMR_multi': 1.423253e-12, 'p_HEIDI': 0.6987305, 'A1': 'A', 'A2': 'C', 'Freq': 0.226994, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.82 | Q19 | Which SNP is most significantly associated with LBD in the Skeletal Muscle? | There are no significantly associated SNPs with LBD in the Skeletal Muscle. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'LBD' AND LOWER(Omic_tissue) = 'skeletal muscle' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.127 | Q19 | Which SNP is most significantly associated with PSP in the Whole Blood? | The most significantly associated SNP with PSP in the Whole Blood is rs11012, located in the ARHGAP27 gene, with an adjusted SMR multi-SNP P-value of 1.36e-13 and a HEIDI value of 7.9699e-02. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PSP' AND LOWER(Omic_tissue) = 'whole blood' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1041707', 'topRSID': 'rs11012', 'Disease': 'PSP', 'Omic_tissue': 'Whole Blood', 'p_SMR_multi': 1.359097e-13, 'p_HEIDI': 0.07969932, 'A1': 'T', 'A2': 'C', 'Freq': 0.191207, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.116 | Q19 | Which SNP is most significantly associated with PSP in the Frontal Cortex? | There are no significantly associated SNPs with PSP in the Frontal Cortex. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PSP' AND LOWER(Omic_tissue) = 'frontal cortex' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.64 | Q19 | Which SNP is most significantly associated with FTD in the Whole Blood? | There are no significantly associated SNPs with FTD in the Whole Blood. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'FTD' AND LOWER(Omic_tissue) = 'whole blood' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.46 | Q19 | Which SNP is most significantly associated with FTD in the Anterior Cingulate Cortex BA24? | There are no significantly associated SNPs with FTD in the Anterior Cingulate Cortex BA24. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'FTD' AND LOWER(Omic_tissue) = 'anterior cingulate cortex ba24' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.5 | Q19 | Which SNP is most significantly associated with AD in the Cerebellar Hemisphere? | The most significantly associated SNP with AD in the Cerebellar Hemisphere is rs1623264, located in the PVRIG gene, with an adjusted SMR multi-SNP P-value of 1.92e-07 and a HEIDI value of 2.0119e-01. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND LOWER(Omic_tissue) = 'cerebellar hemisphere' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1172874', 'topRSID': 'rs1623264', 'Disease': 'AD', 'Omic_tissue': 'Cerebellar Hemisphere', 'p_SMR_multi': 1.917735e-07, 'p_HEIDI': 0.2011887, 'A1': 'C', 'A2': 'G', 'Freq': 0.736196, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.19 | Q19 | Which SNP is most significantly associated with AD in the Substantia nigra? | The most significantly associated SNP with AD in the Substantia nigra is rs1987580, located in the STAG3 gene, with an adjusted SMR multi-SNP P-value of 5.98e-07 and a HEIDI value of 1.3896e-02. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND LOWER(Omic_tissue) = 'substantia nigra' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1446227', 'topRSID': 'rs1987580', 'Disease': 'AD', 'Omic_tissue': 'Substantia nigra', 'p_SMR_multi': 5.982321e-07, 'p_HEIDI': 0.01389594, 'A1': 'C', 'A2': 'A', 'Freq': 0.295501, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.97 | Q19 | Which SNP is most significantly associated with PD in the Hypothalamus? | The most significantly associated SNP with PD in the Hypothalamus is rs55974014, located in the RP11-259G18.3 gene, with an adjusted SMR multi-SNP P-value of 1.15e-11 and a HEIDI value of 3.4628e-01. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND LOWER(Omic_tissue) = 'hypothalamus' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1462897', 'topRSID': 'rs55974014', 'Disease': 'PD', 'Omic_tissue': 'Hypothalamus', 'p_SMR_multi': 1.146115e-11, 'p_HEIDI': 0.346278, 'A1': 'A', 'A2': 'C', 'Freq': 0.226994, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.37 | Q19 | Which SNP is most significantly associated with ALS in the Prefrontal Cortex? | There are no significantly associated SNPs with ALS in the Prefrontal Cortex. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND LOWER(Omic_tissue) = 'prefrontal cortex' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.96 | Q19 | Which SNP is most significantly associated with PD in the Hippocampus? | The most significantly associated SNP with PD in the Hippocampus is rs56040418, located in the CRHR1-IT1 gene, with an adjusted SMR multi-SNP P-value of 9.21e-12 and a HEIDI value of 9.2065e-01. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND LOWER(Omic_tissue) = 'hippocampus' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1386990', 'topRSID': 'rs56040418', 'Disease': 'PD', 'Omic_tissue': 'Hippocampus', 'p_SMR_multi': 9.214326e-12, 'p_HEIDI': 0.9206501, 'A1': 'T', 'A2': 'C', 'Freq': 0.236196, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.20 | Q19 | Which SNP is most significantly associated with AD in the Tibial Nerve? | The most significantly associated SNP with AD in the Tibial Nerve is rs11769559, located in the EPHA1-AS1 gene, with an adjusted SMR multi-SNP P-value of 1.34e-09 and a HEIDI value of 5.0508e-02. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND LOWER(Omic_tissue) = 'tibial nerve' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1287997', 'topRSID': 'rs11769559', 'Disease': 'AD', 'Omic_tissue': 'Tibial Nerve', 'p_SMR_multi': 1.341267e-09, 'p_HEIDI': 0.05050774, 'A1': 'C', 'A2': 'T', 'Freq': 0.43047, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.122 | Q19 | Which SNP is most significantly associated with PSP in the Putamen Basal Ganglia? | The most significantly associated SNP with PSP in the Putamen Basal Ganglia is rs17692129, located in the NSFP1 gene, with an adjusted SMR multi-SNP P-value of 1.45e-11 and a HEIDI value of 3.9510e-01. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PSP' AND LOWER(Omic_tissue) = 'putamen basal ganglia' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1596828', 'topRSID': 'rs17692129', 'Disease': 'PSP', 'Omic_tissue': 'Putamen Basal Ganglia', 'p_SMR_multi': 1.446027e-11, 'p_HEIDI': 0.3950962, 'A1': 'T', 'A2': 'C', 'Freq': 0.340491, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.11 | Q19 | Which SNP is most significantly associated with AD in the Hypothalamus? | The most significantly associated SNP with AD in the Hypothalamus is rs866500, located in the STAG3 gene, with an adjusted SMR multi-SNP P-value of 6.66e-07 and a HEIDI value of 4.9138e-01. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND LOWER(Omic_tissue) = 'hypothalamus' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1453489', 'topRSID': 'rs866500', 'Disease': 'AD', 'Omic_tissue': 'Hypothalamus', 'p_SMR_multi': 6.65674e-07, 'p_HEIDI': 0.4913814, 'A1': 'G', 'A2': 'A', 'Freq': 0.766871, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.41 | Q19 | Which SNP is most significantly associated with ALS in the Substantia nigra? | There are no significantly associated SNPs with ALS in the Substantia nigra. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND LOWER(Omic_tissue) = 'substantia nigra' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.12 | Q19 | Which SNP is most significantly associated with AD in the Liver? | The most significantly associated SNP with AD in the Liver is rs73045691, located in the APOC4 gene, with an adjusted SMR multi-SNP P-value of 3.17e-11 and a HEIDI value of 4.6883e-01. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND LOWER(Omic_tissue) = 'liver' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1466879', 'topRSID': 'rs73045691', 'Disease': 'AD', 'Omic_tissue': 'Liver', 'p_SMR_multi': 3.171686e-11, 'p_HEIDI': 0.4688313, 'A1': 'A', 'A2': 'G', 'Freq': 0.326176, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.100 | Q19 | Which SNP is most significantly associated with PD in the Nucleus Accumbens Basal? | The most significantly associated SNP with PD in the Nucleus Accumbens Basal is rs55974014, located in the KANSL1-AS1 gene, with an adjusted SMR multi-SNP P-value of 1.08e-12 and a HEIDI value of 7.2357e-02. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND LOWER(Omic_tissue) = 'nucleus accumbens basal' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1730065', 'topRSID': 'rs55974014', 'Disease': 'PD', 'Omic_tissue': 'Nucleus Accumbens Basal', 'p_SMR_multi': 1.078886e-12, 'p_HEIDI': 0.07235706, 'A1': 'A', 'A2': 'C', 'Freq': 0.226994, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.106 | Q19 | Which SNP is most significantly associated with PD in the Tibial Nerve? | The most significantly associated SNP with PD in the Tibial Nerve is rs9936329, located in the KAT8 gene, with an adjusted SMR multi-SNP P-value of 3.76e-08 and a HEIDI value of 6.9711e-02. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND LOWER(Omic_tissue) = 'tibial nerve' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1328410', 'topRSID': 'rs9936329', 'Disease': 'PD', 'Omic_tissue': 'Tibial Nerve', 'p_SMR_multi': 3.760457e-08, 'p_HEIDI': 0.06971106, 'A1': 'T', 'A2': 'G', 'Freq': 0.380368, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.79 | Q19 | Which SNP is most significantly associated with LBD in the Nucleus Accumbens Basal? | There are no significantly associated SNPs with LBD in the Nucleus Accumbens Basal. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'LBD' AND LOWER(Omic_tissue) = 'nucleus accumbens basal' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.1 | Q19 | Which SNP is most significantly associated with AD in the Amygdala? | The most significantly associated SNP with AD in the Amygdala is rs2950520, located in the PVRIG gene, with an adjusted SMR multi-SNP P-value of 2.60e-07 and a HEIDI value of 1.6252e-01. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND LOWER(Omic_tissue) = 'amygdala' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1597706', 'topRSID': 'rs2950520', 'Disease': 'AD', 'Omic_tissue': 'Amygdala', 'p_SMR_multi': 2.603229e-07, 'p_HEIDI': 0.1625242, 'A1': 'C', 'A2': 'T', 'Freq': 0.737219, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.80 | Q19 | Which SNP is most significantly associated with LBD in the Prefrontal Cortex? | The most significantly associated SNP with LBD in the Prefrontal Cortex is rs3806789, located in the RP11-67M1.1 gene, with an adjusted SMR multi-SNP P-value of 1.43e-06 and a HEIDI value of 1.2764e-01. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'LBD' AND LOWER(Omic_tissue) = 'prefrontal cortex' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1226644', 'topRSID': 'rs3806789', 'Disease': 'LBD', 'Omic_tissue': 'Prefrontal Cortex', 'p_SMR_multi': 1.43087e-06, 'p_HEIDI': 0.1276414, 'A1': 'T', 'A2': 'C', 'Freq': 0.489775, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.70 | Q19 | Which SNP is most significantly associated with LBD in the Cerebellar Hemisphere? | There are no significantly associated SNPs with LBD in the Cerebellar Hemisphere. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'LBD' AND LOWER(Omic_tissue) = 'cerebellar hemisphere' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.71 | Q19 | Which SNP is most significantly associated with LBD in the Cerebellum? | There are no significantly associated SNPs with LBD in the Cerebellum. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'LBD' AND LOWER(Omic_tissue) = 'cerebellum' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.13 | Q19 | Which SNP is most significantly associated with AD in the Multi Ancestry Whole Brain? | The most significantly associated SNP with AD in the Multi Ancestry Whole Brain is rs2897358, located in the PILRB gene, with an adjusted SMR multi-SNP P-value of 1.21e-09 and a HEIDI value of 6.5833e-02. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND LOWER(Omic_tissue) = 'multi ancestry whole brain' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1392628', 'topRSID': 'rs2897358', 'Disease': 'AD', 'Omic_tissue': 'Multi Ancestry Whole Brain', 'p_SMR_multi': 1.205748e-09, 'p_HEIDI': 0.06583308, 'A1': 'G', 'A2': 'C', 'Freq': 0.200409, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.43 | Q19 | Which SNP is most significantly associated with ALS in the Whole Blood? | The most significantly associated SNP with ALS in the Whole Blood is rs9969832, located in the C9orf72 gene, with an adjusted SMR multi-SNP P-value of 6.71e-11 and a HEIDI value of 6.8091e-01. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND LOWER(Omic_tissue) = 'whole blood' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_745098', 'topRSID': 'rs9969832', 'Disease': 'ALS', 'Omic_tissue': 'Whole Blood', 'p_SMR_multi': 6.714586e-11, 'p_HEIDI': 0.6809056, 'A1': 'T', 'A2': 'C', 'Freq': 0.233129, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.32 | Q19 | Which SNP is most significantly associated with ALS in the Hippocampus? | There are no significantly associated SNPs with ALS in the Hippocampus. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND LOWER(Omic_tissue) = 'hippocampus' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.28 | Q19 | Which SNP is most significantly associated with ALS in the Cerebellum? | There are no significantly associated SNPs with ALS in the Cerebellum. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND LOWER(Omic_tissue) = 'cerebellum' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.25 | Q19 | Which SNP is most significantly associated with ALS in the Basal Ganglia? | There are no significantly associated SNPs with ALS in the Basal Ganglia. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND LOWER(Omic_tissue) = 'basal ganglia' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.95 | Q19 | Which SNP is most significantly associated with PD in the Frontal Cortex? | The most significantly associated SNP with PD in the Frontal Cortex is rs62057151, located in the LRRC37A4P gene, with an adjusted SMR multi-SNP P-value of 2.03e-12 and a HEIDI value of 7.4811e-01. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND LOWER(Omic_tissue) = 'frontal cortex' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1168831', 'topRSID': 'rs62057151', 'Disease': 'PD', 'Omic_tissue': 'Frontal Cortex', 'p_SMR_multi': 2.026026e-12, 'p_HEIDI': 0.7481131, 'A1': 'T', 'A2': 'C', 'Freq': 0.241309, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.112 | Q19 | Which SNP is most significantly associated with PSP in the Caudate Basal Ganglia? | There are no significantly associated SNPs with PSP in the Caudate Basal Ganglia. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PSP' AND LOWER(Omic_tissue) = 'caudate basal ganglia' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.93 | Q19 | Which SNP is most significantly associated with PD in the Cerebellum? | The most significantly associated SNP with PD in the Cerebellum is rs1991556, located in the LRRC37A4P gene, with an adjusted SMR multi-SNP P-value of 5.01e-13 and a HEIDI value of 3.5028e-02. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND LOWER(Omic_tissue) = 'cerebellum' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1710342', 'topRSID': 'rs1991556', 'Disease': 'PD', 'Omic_tissue': 'Cerebellum', 'p_SMR_multi': 5.010673e-13, 'p_HEIDI': 0.0350284, 'A1': 'A', 'A2': 'G', 'Freq': 0.238241, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.16 | Q19 | Which SNP is most significantly associated with AD in the Putamen Basal Ganglia? | The most significantly associated SNP with AD in the Putamen Basal Ganglia is rs1623264, located in the PVRIG gene, with an adjusted SMR multi-SNP P-value of 2.79e-07 and a HEIDI value of 8.5606e-02. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND LOWER(Omic_tissue) = 'putamen basal ganglia' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1583222', 'topRSID': 'rs1623264', 'Disease': 'AD', 'Omic_tissue': 'Putamen Basal Ganglia', 'p_SMR_multi': 2.788121e-07, 'p_HEIDI': 0.08560628, 'A1': 'C', 'A2': 'G', 'Freq': 0.736196, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.78 | Q19 | Which SNP is most significantly associated with LBD in the Multi Ancestry Whole Brain? | There are no significantly associated SNPs with LBD in the Multi Ancestry Whole Brain. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'LBD' AND LOWER(Omic_tissue) = 'multi ancestry whole brain' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.23 | Q19 | Which SNP is most significantly associated with ALS in the Amygdala? | There are no significantly associated SNPs with ALS in the Amygdala. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND LOWER(Omic_tissue) = 'amygdala' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.48 | Q19 | Which SNP is most significantly associated with FTD in the Caudate Basal Ganglia? | There are no significantly associated SNPs with FTD in the Caudate Basal Ganglia. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'FTD' AND LOWER(Omic_tissue) = 'caudate basal ganglia' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.66 | Q19 | Which SNP is most significantly associated with LBD in the Amygdala? | There are no significantly associated SNPs with LBD in the Amygdala. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'LBD' AND LOWER(Omic_tissue) = 'amygdala' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.107 | Q19 | Which SNP is most significantly associated with PD in the Whole Blood? | The most significantly associated SNP with PD in the Whole Blood is rs55974014, located in the RP11-707O23.5 gene, with an adjusted SMR multi-SNP P-value of 2.14e-15 and a HEIDI value of 1.0447e-01. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND LOWER(Omic_tissue) = 'whole blood' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1679563', 'topRSID': 'rs55974014', 'Disease': 'PD', 'Omic_tissue': 'Whole Blood', 'p_SMR_multi': 2.139585e-15, 'p_HEIDI': 0.104475, 'A1': 'A', 'A2': 'C', 'Freq': 0.226994, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.31 | Q19 | Which SNP is most significantly associated with ALS in the Frontal Cortex? | There are no significantly associated SNPs with ALS in the Frontal Cortex. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND LOWER(Omic_tissue) = 'frontal cortex' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.85 | Q19 | Which SNP is most significantly associated with LBD in the Tibial Nerve? | There are no significantly associated SNPs with LBD in the Tibial Nerve. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'LBD' AND LOWER(Omic_tissue) = 'tibial nerve' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.68 | Q19 | Which SNP is most significantly associated with LBD in the Basal Ganglia? | There are no significantly associated SNPs with LBD in the Basal Ganglia. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'LBD' AND LOWER(Omic_tissue) = 'basal ganglia' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.10 | Q19 | Which SNP is most significantly associated with AD in the Hippocampus? | The most significantly associated SNP with AD in the Hippocampus is rs34130487, located in the STAG3 gene, with an adjusted SMR multi-SNP P-value of 2.18e-07 and a HEIDI value of 5.5343e-01. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND LOWER(Omic_tissue) = 'hippocampus' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1377707', 'topRSID': 'rs34130487', 'Disease': 'AD', 'Omic_tissue': 'Hippocampus', 'p_SMR_multi': 2.179524e-07, 'p_HEIDI': 0.5534318, 'A1': 'T', 'A2': 'C', 'Freq': 0.278119, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.34 | Q19 | Which SNP is most significantly associated with ALS in the Liver? | There are no significantly associated SNPs with ALS in the Liver. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND LOWER(Omic_tissue) = 'liver' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.67 | Q19 | Which SNP is most significantly associated with LBD in the Anterior Cingulate Cortex BA24? | There are no significantly associated SNPs with LBD in the Anterior Cingulate Cortex BA24. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'LBD' AND LOWER(Omic_tissue) = 'anterior cingulate cortex ba24' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.26 | Q19 | Which SNP is most significantly associated with ALS in the Caudate Basal Ganglia? | There are no significantly associated SNPs with ALS in the Caudate Basal Ganglia. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND LOWER(Omic_tissue) = 'caudate basal ganglia' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.75 | Q19 | Which SNP is most significantly associated with LBD in the Hippocampus? | There are no significantly associated SNPs with LBD in the Hippocampus. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'LBD' AND LOWER(Omic_tissue) = 'hippocampus' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.29 | Q19 | Which SNP is most significantly associated with ALS in the Cerebral Spinal Fluid? | There are no significantly associated SNPs with ALS in the Cerebral Spinal Fluid. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND LOWER(Omic_tissue) = 'cerebral spinal fluid' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.58 | Q19 | Which SNP is most significantly associated with FTD in the Prefrontal Cortex? | There are no significantly associated SNPs with FTD in the Prefrontal Cortex. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'FTD' AND LOWER(Omic_tissue) = 'prefrontal cortex' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.126 | Q19 | Which SNP is most significantly associated with PSP in the Tibial Nerve? | There are no significantly associated SNPs with PSP in the Tibial Nerve. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PSP' AND LOWER(Omic_tissue) = 'tibial nerve' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.54 | Q19 | Which SNP is most significantly associated with FTD in the Hypothalamus? | There are no significantly associated SNPs with FTD in the Hypothalamus. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'FTD' AND LOWER(Omic_tissue) = 'hypothalamus' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.6 | Q19 | Which SNP is most significantly associated with AD in the Cerebellum? | The most significantly associated SNP with AD in the Cerebellum is rs34130487, located in the STAG3 gene, with an adjusted SMR multi-SNP P-value of 1.18e-09 and a HEIDI value of 4.0622e-01. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND LOWER(Omic_tissue) = 'cerebellum' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1687933', 'topRSID': 'rs34130487', 'Disease': 'AD', 'Omic_tissue': 'Cerebellum', 'p_SMR_multi': 1.184878e-09, 'p_HEIDI': 0.406217, 'A1': 'T', 'A2': 'C', 'Freq': 0.278119, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.69 | Q19 | Which SNP is most significantly associated with LBD in the Caudate Basal Ganglia? | There are no significantly associated SNPs with LBD in the Caudate Basal Ganglia. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'LBD' AND LOWER(Omic_tissue) = 'caudate basal ganglia' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.99 | Q19 | Which SNP is most significantly associated with PD in the Multi Ancestry Whole Brain? | The most significantly associated SNP with PD in the Multi Ancestry Whole Brain is rs55974014, located in the KANSL1-AS1 gene, with an adjusted SMR multi-SNP P-value of 5.69e-16 and a HEIDI value of 1.4916e-02. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND LOWER(Omic_tissue) = 'multi ancestry whole brain' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [{'UUID': 'NDD_SMR_genes_all_update_text_1435918', 'topRSID': 'rs55974014', 'Disease': 'PD', 'Omic_tissue': 'Multi Ancestry Whole Brain', 'p_SMR_multi': 5.6905e-16, 'p_HEIDI': 0.01491641, 'A1': 'A', 'A2': 'C', 'Freq': 0.226994, 'func_sig': 'functionally significant'}] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Q19.40 | Q19 | Which SNP is most significantly associated with ALS in the Spinalcord? | There are no significantly associated SNPs with ALS in the Spinalcord. | SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
FROM `{project_id}.{dataset_name}.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND LOWER(Omic_tissue) = 'spinalcord' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
ORDER BY p_SMR_multi
LIMIT 1 | [] | refined | Select, Multi-Filter, Order By, Threshold | Functional Significance |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.